How GLP-1 Treatments Support Weight Loss GLP-1 treatments promote weight loss by helping you feel full longer and reducing food cravings
Most recently, PAGln levels were positively associated with heart failure, independent of ejection fraction, and shown to have mechanistic links to relevant CV phenotypes in several studies 12
These treatments should be offered to adults who meet all of the following: At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) BMI of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) Access to a specialist weight management service that provides multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions Treatment is typically time-limited to up to 2 years Previous unsuccessful attempts at weight loss through lifestyle measures alone Orlistat may be considered for adults with a BMI of 28 kg/m or above with associated risk factors (such as type 2 diabetes or cardiovascular disease), or 30 kg/m or above without additional risk factors
The most important step is a conversation with a provider who can review your goals, lifestyle, and health history before recommending a plan
One copper ion
Heres a fun way to think about it: Imagine your body as a sponge
